Cencora Announces CFO Retirement and Reaffirms 2026 Financial Guidance

Key Highlights for Investors

• Executive Transition: James F. Cleary, Executive Vice President and Chief Financial Officer (CFO), will retire effective June 30, 2026. Cencora has engaged an executive search firm to identify his successor, considering both internal and external candidates.
• Succession Planning: Cleary will assist in the search process and remain as an advisor through the end of 2026 to ensure a smooth leadership transition.
• Leadership Legacy: Cleary has served as CFO since November 2018 and previously as CEO of MWI Veterinary Supply, which Cencora acquired in 2015. He is credited with over 20 years of public company executive experience, driving growth and shareholder value.
• Financial Guidance Reaffirmed: Cencora reiterated its adjusted diluted EPS guidance of \$17.45 to \$17.75 for fiscal year 2026, signaling management’s confidence in the company’s near-term outlook despite the upcoming leadership change.
• Corporate Profile: Cencora is a Fortune 500 (#10 US, #18 Global) pharmaceutical solutions leader, with over \$300 billion in annual revenue and 51,000+ employees globally.

Details of the Financial Leadership Transition

Cencora, Inc. (NYSE: COR) announced a significant leadership transition as James F. Cleary, aged 62, plans to retire as Executive Vice President and Chief Financial Officer, effective June 30, 2026. Cleary, who has been with Cencora since 2015 following its acquisition of MWI Veterinary Supply (where he was CEO for over a decade), has served as Cencora’s CFO since November 2018.

The company has retained an executive search firm to facilitate the identification and evaluation of potential successors. The search will include both internal and external candidates, underscoring the importance of this role to Cencora’s future strategy and financial leadership. Cleary will play an active role in the transition, both by participating in the search process and by serving in an advisory capacity through the end of 2026.

Management and Board Commentary

“On behalf of the Board and Enterprise Leadership Team, I want to thank Jim for his years of pragmatic leadership, strategic insight and consistent financial stewardship. Jim retires with an outstanding track record of driving growth and shareholder value during his over 20 years as a public company executive,” said Robert P. Mauch, President and Chief Executive Officer of Cencora.

Mark Durcan, Chair of Cencora’s Board of Directors, added, “He is a consistent, thoughtful and practical leader with a demonstrated track record of connecting strategic vision and business acumen for the organizations he’s been a part of. We appreciate that Jim will remain with Cencora for the next several months and we wish him the best in his next chapter.”

Cleary commented, “Working with this team has been the highlight of my career. I’m very proud of what we accomplished together at Cencora, enhancing value for all stakeholders. As I step into my next chapter, I do so with great confidence in Cencora and the talented people across the company.”

Financial Guidance and Outlook

Importantly for shareholders, Cencora reaffirmed its previously issued adjusted diluted EPS guidance range of \$17.45 to \$17.75 for fiscal year 2026. This move is designed to reassure investors that the company’s financial fundamentals remain robust and that the succession process is not expected to disrupt its operational or financial trajectory.

Cencora’s leadership emphasized their confidence in the company’s ability to continue creating value for stakeholders and successfully navigating the transition period.

About Cencora

Cencora is a leading global pharmaceutical solutions organization, partnering with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. The company is central to the secure and reliable delivery of pharmaceuticals, healthcare products, and solutions, serving both people and animals. With over 51,000 employees worldwide and annual revenues exceeding \$300 billion, Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 lists.

Potential Price-Sensitive Information

• CFO Succession: The retirement of a long-serving and highly regarded CFO introduces a degree of uncertainty, but the company’s proactive search for a successor and Cleary’s ongoing involvement reduce execution risk.
• Guidance Reaffirmation: Reaffirming financial guidance during a major executive transition can be interpreted positively by investors, signaling management’s confidence in business continuity and near-term performance.

Forward-Looking Statements Disclaimer

This article contains forward-looking statements that reflect Cencora’s current expectations regarding future events, including leadership transitions and financial outlook. Actual results could differ materially due to various risks and uncertainties, as detailed in Cencora’s filings with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise forward-looking statements except as required by law. Investors are encouraged to review all relevant filings and consult their financial advisors before making investment decisions.

View Cencora, Inc. Historical chart here